AIM: To evaluate the image quality of hepatic multidetector computed tomography (MDCT) with dynamic contrast enhancement. METHODS: It uses iodixanol 270 mg/mL (Visipaque 270) and 80 kVp acquisitions reconstructed with sinogram affirmed iterative reconstruction (SAFIRE(®)) in comparison with a standard MDCT protocol. Fifty-three consecutive patients with known or suspected hepatocellular carcinoma underwent 55 CT examinations, with two different four-phase CT protocols. The first group of 30 patients underwent a standard 120 kVp acquisition after injection of Iohexol 350 mg/mL (Accupaque 350(®)) and reconstructed with filtered back projection. The second group of 25 patients underwent a dual-energy CT at 80-140 kVp with iodixanol 270. The 80 kVp component of the second group was reconstructed iteratively (SAFIRE(®)-Siemens). All hyperdense and hypodense hepatic lesions ≥ 5 mm were identified with both protocols. Aorta and portal vessels/liver parenchyma contrast to noise ratio (CNR) in arterial phase, hypervascular lesion/liver parenchyma CNR in arterial phase, hypodense lesion/liver parenchyma CNR in portal and late phase were calculated in both groups. RESULTS: Aorta/liver and focal lesions altogether/liver CNR were higher for the second protocol (P = 0.0078 and 0.0346). Hypervascular lesions/liver CNR was not statistically different (P = 0.86). Hypodense lesion/liver CNR in the portal phase was significantly higher for the second group (P = 0.0107). Hypodense lesion/liver CNR in the late phase was the same for both groups (P = 0.9926). CONCLUSION: MDCT imaging with 80 kVp with iterative reconstruction and iodixanol 270 yields equal or even better image quality.
AIM: To evaluate the image quality of hepatic multidetector computed tomography (MDCT) with dynamic contrast enhancement. METHODS: It uses iodixanol 270 mg/mL (Visipaque 270) and 80 kVp acquisitions reconstructed with sinogram affirmed iterative reconstruction (SAFIRE(®)) in comparison with a standard MDCT protocol. Fifty-three consecutive patients with known or suspected hepatocellular carcinoma underwent 55 CT examinations, with two different four-phase CT protocols. The first group of 30 patients underwent a standard 120 kVp acquisition after injection of Iohexol 350 mg/mL (Accupaque 350(®)) and reconstructed with filtered back projection. The second group of 25 patients underwent a dual-energy CT at 80-140 kVp with iodixanol 270. The 80 kVp component of the second group was reconstructed iteratively (SAFIRE(®)-Siemens). All hyperdense and hypodense hepatic lesions ≥ 5 mm were identified with both protocols. Aorta and portal vessels/liver parenchyma contrast to noise ratio (CNR) in arterial phase, hypervascular lesion/liver parenchyma CNR in arterial phase, hypodense lesion/liver parenchyma CNR in portal and late phase were calculated in both groups. RESULTS: Aorta/liver and focal lesions altogether/liver CNR were higher for the second protocol (P = 0.0078 and 0.0346). Hypervascular lesions/liver CNR was not statistically different (P = 0.86). Hypodense lesion/liver CNR in the portal phase was significantly higher for the second group (P = 0.0107). Hypodense lesion/liver CNR in the late phase was the same for both groups (P = 0.9926). CONCLUSION: MDCT imaging with 80 kVp with iterative reconstruction and iodixanol 270 yields equal or even better image quality.
Authors: Daniele Marin; Kingshuk Roy Choudhury; Rajan T Gupta; Lisa M Ho; Brian C Allen; Sebastian T Schindera; James G Colsher; Ehsan Samei; Rendon C Nelson Journal: Eur Radiol Date: 2013-07-06 Impact factor: 5.315
Authors: Daniele Marin; Rendon C Nelson; Ehsan Samei; Erik K Paulson; Lisa M Ho; Daniel T Boll; David M DeLong; Terry T Yoshizumi; Sebastian T Schindera Journal: Radiology Date: 2009-04-03 Impact factor: 11.105
Authors: Daniele Marin; Rendon C Nelson; Sebastian T Schindera; Samuel Richard; Richard S Youngblood; Terry T Yoshizumi; Ehsan Samei Journal: Radiology Date: 2010-01 Impact factor: 11.105